REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Prof. Andreas BuschJanuary 2011. An unmasked account of decisions about investing into cancer stem cell research and the fate of regenerative medicine projects in Japan. Dr Busch summarises results and evaluates technology platforms like novel antibodies and wnt mechanisms. He voices his expectations from current key drug development partnerships, in particular with Oncomed and Micromet. Will these include companion diagnostics? To what extent does Bayer retain respective intellectual property rights? A comment on personalised medicine and cancer stem cells research pursued by Merck KGaA and others. What are prospects for classic oncology drugs?

 

 

 

Related Articles

Horizon Discovery: Mitigating risks and developing the U.S. business

Tasks ahead for Eric Rhodes, the new CTO

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

Prof Walter Kolch on the approach taken by Systems Biology Ireland


B2Bioworld Stem Cell Insights Collection 2010:

Issues and Evaluation from Pharma Leaders

 

Dr Patrick Vallance, GSK:

Stem Cell Research Now and in the Future

 

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

3 pages, exclusive

Lilly Ventures: Is it worth a dollar, or a million dollars?

Ed Torres, Managing Director of Lilly Ventures on the fund’s input to Eli Lilly’s business development

S. Edward TorresDecember 2010. What strategies is Lilly’s Venture Fund pursuing in the US and Latin America. Ed Torres, Managing Director of Lilly Ventures describes for B2Bioworld investment policies in biotechnology, medical technologies, and healthcare IT, as well as future plans. There will be a marked change with regard to the Fund’s approach in Europe. But what is at stake, when non-profit organisations have a major say? Moreover, what is the critical input to the parent company in developing its global business and filling up the pipeline. Includes a detailed overview on current investments as well as co-investors compiled by B2Bioworld.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

in-depth enquiry, noPR,7 pages

More accolade for Steven Ley - A Pioneer in Organic Chemistry

29 October 2009. Prof. Steven Ley, Head of the Department at Cambridge University received another prestigious science award, the Heinrich-Wieland-Prize sponsored by Boehringer Ingelheim. This is his third award after the Royal Society of Chemistry’s Perkin Prize for Organic Chemistry and the Tetrahedron Prize for Creativity in Organic Chemistry from Elsevier. A spokesperson of Boehringer Ingelheim said at the occasion that with awarding the Heinrich Wieland Prize Boehringer Ingelheim aims to foster research on lipids and other biologically active substances in the areas of chemistry, biochemistry, physiology as well as clinical medicine. Since 1964 60 scientists have received the prize including Nobel laureates 1985 Michael Brown and Joseph Goldstein.


Prof. Steven Ley Lab (C) University of Cambridge 2009

Steven Victor Ley was born in 1945. He obtained his PhD in Chemistry at Loughborough University in 1972. Thereafter he performed post-doctoral research at Ohio State University and Imperial College where he became later Head of Department. In 1992 he was nominated BP (1702) Professor of Organic Chemistry at the University of Cambridge.
Prof. Ley is a pioneer in green chemistry and an expert in the synthesis of natural products. In is Cambridge Laboratory named after Thomas Whiffen he follows the tradition of the reputed alkaloid chemist and entrepreneur. Here Ley achieved total synthesis of more than 120 natural compounds, such as Bengazole A and B, a new class of lipophilic molecules with antifungal activity (c.p.: http://leygroup.ch.cam.ac.uk/natprodpapers.html). He is the inventor of Tetra-n-butylammonium Per-ruthenate TPAP reagent), which is a widely used catalytic oxidant. His research on synthesis of biologically active substances having an acetylene skeleton in the molecule, or an organic functional material has led up to catalysts applicable for manufacture of polymer materials, liquid crystals or optical materials. Ley’s scientific work then is of equal interest to the chemicals, pharmaceutical, agro and electronic industries with major companies such as AstraZeneca, BASF, Daihatsu, GlaxoSmithKline, Novartis, Roche, or Wyeth.


With more specific regard to pharma intermediates and drugs more recent achievements are on elucidating the regulation of the ERK/MAP kinase signalling pathway by Tumor Progression Locus-2 (TPL-2) important for modulating inflammatory response. It is leading up to powerful inhibitors which are currently under development. Another recent examples are the synthesis of the C‑reactive protein inhibitor compound designed by Mark Pepys, Royal Free Hospital (UK) as well as development of small molecule ligands to treat transthyretin amyloidosis with Pepys and Vittorio Bellotti, Università degli Studi di Pavia (IT). “Both projects are at the top level of scientific originality, and have been recognised as such by both major scientific prizes and grant awards, and of great potential medical significance” Mark Pepys comments on the collaboration with his colleague Steve Ley. Amyloidosis is a disease caused by extracellular deposition of insoluble abnormal fibrils. It predominantly affects the heart, but also eyes and kidney. It is rare in Caucasians, but medical epidemiologist estimate that it some 1.3 million Afro Americans are carriers of this disease. The development of a combined small molecule-antibody to treat amyloidosis is currently commercialised in Pentraxin Therapeutics Ltd. for GSK. Several other companies are developing Prof. Ley’s research into products such as Chiroscience (UCB Celltech) at Slough. A second area of interest towards major efforts are dedicated is development of enabling technologies for organic synthesis in the so-called Innovative Technology Centre at Cambridge. This is resulting in a number of industrially attractive methods in microfluidic flow chemistry or instruments like microwave reactors for automated syntheses. While supporting technology transfer throughout his career he is not actively taking major roles in these firms.

 

Prof. Steven Ley (C) University of Cambridge 2009Prof. Steven V. Ley holds the oldest continuously occupied chair of chemistry in Britain.

Stem Cell Insights Collection 2010

Issues and Evaluation from Pharma Leaders

How does the pharma industry view application of stem cell technologies? Where are R&D efforts needed, and where does academic research not fulfill expectations? What is the role of suppliers in the field?

Read fresh answers from the leaders, provided exclusively to readers of B2Bioworld. Published only here, and all in one.

 

(C) Boehringer Ingelheim(C) Wolf G Kroner 2009(C) Wolf G Kroner 2009(C) Hoffmann-La Roche 2009

 

We are obliged to more and more move away from animal models
- Prof. Andreas Barner, Boehringer Ingelheim


Preparing for Another Level of Innovation
- Dr Mark Fishman, Novartis


Clear away complete confusion of terms
- Dr Bernhard Kirschbaum, Merck Serono


Stem Cells: a discovery tool and a potential therapeutic modality
- Dr Jonathan Knowles, Hoffmann-La Roche

 

(C) R.McKernan 2009(C) Wolf G Kroner 2009(C) M. Krogsgaard(C) K. Stoeckli

 

It really started last year…
- Dr Ruth McKernan, Pfizer Regenerative Medicine


Stem Cells and Vaccines Production
- Dr Majid Mehtali, Vivalis


Doing our business a little bit differently than the others in the industry
- Dr Mads Krogsgaard, Novo Nordisk


Triggering Regenerative Functions with Transplanted Cells and Small Molecules
- Dr Kurt Stoeckli, Biological Sciences/Discovery Sanofi-Aventis

 

(C) P. Vallance(C) Hugh Ilyine 2009(C) S. Tegethoff 2009(C) D. Hay 2009


Stem Cell Research in GlaxoSmithKline and Beyond
- Dr Patrick Vallance, GlaxoSmithKline Drug Discovery


Stem Cells – Failings and Deliveries
- Hugh Ilyine, Consultant & Guest Editor


Patenting Stem Cells
- Dr. Sebastian Tegethoff, 24IP


Drug Testing with Embryonic Stem Cells – Towards Standards For Assays
– Dr David C Hay, University of Edinburgh, MRC Centre for Regenerative Medicine


L’Oréal avance dans les cellules souches
- Report by Hélène Guyot (with summary in English)


Buy the Entire Collection of Articles on Stem Cells here

 

Related Article 

Bayer AG: New Stakes in Stem Cells
- Prof. Andreas Busch, Bayer AG



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

13 articles, advert-free

Top 10 Tags

All Tags (2094)